search
Back to results

VIdeo Assisted Thoracoscopic Lobectomy Versus Conventional Open LobEcTomy for Lung Cancer (VIOLET)

Primary Purpose

Lung Neoplasms

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Open Surgery
Video Assisted Thoracoscopic Surgery (VATS)
Sponsored by
University of Bristol
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Neoplasms focused on measuring lung, cancer, lobectomy

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults aged ≥16 years of age
  2. Able to give written consent, undergoing either:

    i. Lobectomy or bilobectomy for treatment of known or suspected primary lung cancer beyond lobar orifice* in TNM8 stage cT1-3 (by size criteria, equivalent to TNM7 stage cT1a-2b) or cT3 (by virtue of 2 nodules in the same lobe), N0-1 and M0 or ii. Undergoing frozen section biopsy with the intention to proceed with lobectomy or bilobectomy if primary lung cancer with a peripheral tumour beyond a lobar orifice* in TNM8 stage cT1-3 (by size criteria, equivalent to TNM7 stage cT1a-2b) or cT3 (by virtue of 2 nodules in the same lobe), N0-1 and M0 is confirmed

  3. Disease suitable for both minimal access (VATS) and open surgery

Exclusion Criteria:

  1. Adults lacking capacity to consent
  2. Previous malignancy that influences life expectancy
  3. Patients in whom a pneumonectomy, segmentectomy or non-anatomic resection (e.g. wedge resection) is planned
  4. Patients with a serious concomitant disorder that would compromise patient safety during surgery.
  5. Planned robotic surgery

Sites / Locations

  • Heartlands Hospital
  • Bristol Royal Infirmary
  • Royal Infirmary of Edinburgh
  • Hull and East Yorkshire Hospitals NHS Trust
  • Liverpool Heart and Chest Hospital NHS Foundation Trust
  • Harefield Hospital
  • Royal Brompton Hospital
  • The James Cook University Hospital
  • Oxford University Hospitals NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

VATS lobectomy

Open lobectomy

Arm Description

VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.

Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.

Outcomes

Primary Outcome Measures

Self-reported physical function using HRQoL questionnaire QLQ-C30
Physical functioning scale, ranges between 0 and 100. High score indicates high level of physical functioning.

Secondary Outcome Measures

Time from surgery to hospital discharge, assessed up to 12 months
Adverse health events to 1 year
Proportion of patients taking up adjuvant treatment, assessed up to 12 months
Time to uptake of adjuvant treatment, assessed up to 12 months
Proportion of patients upstaged to pN2 disease after surgical procedure, assessed up to 3 months post surgery
Overall and disease-free survival to 1-year
Proportion of patients who undergo complete resection during the procedure, , assessed up to 12 months
Proportion of patients who experience prolonged incision pain (defined as the need of analgesia > 5 weeks post-randomisation)
Disease-specific HRQoL - EORTC QLQ-C30 to 1-year
3 types of scales. Functioning scales which include physical functioning, role functioning, emotional function, cognitive functioning and social functioning. Symptom scales which include fatigue, nausea and vomiting, pain, dysponea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties. An overall global health status/QoL All scales range between 0 and 100. For functioning scales, a high score indicates a high level of functioning. Similarly, a high global health status/QoL score indicates a high quality of life. For symptom scales, a high score indicates a high level of symptoms.
Disease-specific HRQoL - EORTC QLQ-LC13 to 1-year
Symptoms scales which include Dyspnoea, Couging, Haemoptysis, Sore mouth, Dysphagia, Peripheral neuropathy, Alopecia, Pain in chest, Pain in arm or shoulder, Pain in other parts, and Pain medication. For these scales, a high score indicates a high level of symptoms, as with the QLQ-C30. Scales range between 0 and 100.
Generic HRQoL - EORTC EQ5D to 1-year
Subscales: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. These range from 1-5. subscales mobility, self-care, usual activities, pain/discomfort, anxiety/depression are combined to calculate an overall index score which ranges from -0.59 to 1. A higher score indicates better quality of life
Resource use
Resource use to 1-year (measured for the duration of post-operative hospital stay until discharge, and at 5 weeks, 3 months, 6 months and 1-year post randomisation)

Full Information

First Posted
January 26, 2018
Last Updated
September 18, 2020
Sponsor
University of Bristol
Collaborators
Royal Brompton & Harefield NHS Foundation Trust, University of Oxford
search

1. Study Identification

Unique Protocol Identification Number
NCT03521375
Brief Title
VIdeo Assisted Thoracoscopic Lobectomy Versus Conventional Open LobEcTomy for Lung Cancer
Acronym
VIOLET
Official Title
VIdeo Assisted Thoracoscopic Lobectomy Versus Conventional Open LobEcTomy for Lung Cancer, a Multi-centre Randomised Controlled Trial With an Internal Pilot
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
July 2015 (undefined)
Primary Completion Date
March 2019 (Actual)
Study Completion Date
March 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Bristol
Collaborators
Royal Brompton & Harefield NHS Foundation Trust, University of Oxford

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Lung cancer is the leading cause of cancer death worldwide and survival in the United Kingdom (UK) remains amongst the lowest in Europe. Surgery is the main method of managing early stage disease and is traditionally undertaken via conventional open surgery. However, over the last decade there has been a surge in the number of minimal access resections performed using Video-assisted thoracoscopic surgery (VATS). However, there remains a need for well-designed and conducted randomised controlled trial (RCT) to provide the evidence base for the wide spread uptake and delivery of this surgical approach.
Detailed Description
The uptake of surgery for lung cancer in the UK is low and minimal access surgery may be regarded as a more acceptable intervention (compared to open surgery) by patients, referring respiratory physicians and oncologists. However, a large multi-centre RCT is essential to inform patient and clinician decision making and influence surgical practice in the UK. The VIOLET study will compare the effectiveness, cost-effectiveness and acceptability of VATS lobectomy versus open surgery for treatment of lung cancer and will test the hypothesis that VATS surgery is superior to open surgery with respect to self-reported physical function five weeks after randomisation (approx. one month after surgery). Specific objectives are to estimate: A. The difference between groups in the average self-reported physical function at five weeks. B. The difference between groups with respect to a range of secondary outcomes including assessment of efficacy (hospital stay, pain, proportion and time to uptake of chemotherapy), measures of safety (adverse health events), oncological outcomes (proportion of patients upstaged to pN2 disease and disease free survival) and overall survival. C. The cost effectiveness of VATs and open surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Neoplasms
Keywords
lung, cancer, lobectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
503 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VATS lobectomy
Arm Type
Experimental
Arm Description
VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
Arm Title
Open lobectomy
Arm Type
Active Comparator
Arm Description
Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
Intervention Type
Procedure
Intervention Name(s)
Open Surgery
Other Intervention Name(s)
Open lobectomy
Intervention Description
Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
Intervention Type
Procedure
Intervention Name(s)
Video Assisted Thoracoscopic Surgery (VATS)
Other Intervention Name(s)
VATS lobectomy
Intervention Description
VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
Primary Outcome Measure Information:
Title
Self-reported physical function using HRQoL questionnaire QLQ-C30
Description
Physical functioning scale, ranges between 0 and 100. High score indicates high level of physical functioning.
Time Frame
5 weeks post randomisation
Secondary Outcome Measure Information:
Title
Time from surgery to hospital discharge, assessed up to 12 months
Time Frame
Time from surgery to hospital discharge, assessed up to 12 months
Title
Adverse health events to 1 year
Time Frame
Adverse health events to 1 year
Title
Proportion of patients taking up adjuvant treatment, assessed up to 12 months
Time Frame
Proportion and time to uptake of adjuvant treatment, assessed up to 12 months
Title
Time to uptake of adjuvant treatment, assessed up to 12 months
Time Frame
Proportion and time to uptake of adjuvant treatment, assessed up to 12 months
Title
Proportion of patients upstaged to pN2 disease after surgical procedure, assessed up to 3 months post surgery
Time Frame
Proportion of patients upstaged to pN2 disease after surgical procedure, assessed up to 3 months post-surgery
Title
Overall and disease-free survival to 1-year
Time Frame
1 year
Title
Proportion of patients who undergo complete resection during the procedure, , assessed up to 12 months
Time Frame
Proportion of patients who undergo complete resection during the procedure, assessed up to 12 months
Title
Proportion of patients who experience prolonged incision pain (defined as the need of analgesia > 5 weeks post-randomisation)
Time Frame
Up to 1 year
Title
Disease-specific HRQoL - EORTC QLQ-C30 to 1-year
Description
3 types of scales. Functioning scales which include physical functioning, role functioning, emotional function, cognitive functioning and social functioning. Symptom scales which include fatigue, nausea and vomiting, pain, dysponea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties. An overall global health status/QoL All scales range between 0 and 100. For functioning scales, a high score indicates a high level of functioning. Similarly, a high global health status/QoL score indicates a high quality of life. For symptom scales, a high score indicates a high level of symptoms.
Time Frame
Measured at 2 week, 5 weeks, 3 months, 6 months and 1-year post randomisation
Title
Disease-specific HRQoL - EORTC QLQ-LC13 to 1-year
Description
Symptoms scales which include Dyspnoea, Couging, Haemoptysis, Sore mouth, Dysphagia, Peripheral neuropathy, Alopecia, Pain in chest, Pain in arm or shoulder, Pain in other parts, and Pain medication. For these scales, a high score indicates a high level of symptoms, as with the QLQ-C30. Scales range between 0 and 100.
Time Frame
Measured at 2 week, 5 weeks, 3 months, 6 months and 1-year post randomisation
Title
Generic HRQoL - EORTC EQ5D to 1-year
Description
Subscales: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. These range from 1-5. subscales mobility, self-care, usual activities, pain/discomfort, anxiety/depression are combined to calculate an overall index score which ranges from -0.59 to 1. A higher score indicates better quality of life
Time Frame
Measured at 2 week, 5 weeks, 3 months, 6 months and 1-year post randomisation
Title
Resource use
Description
Resource use to 1-year (measured for the duration of post-operative hospital stay until discharge, and at 5 weeks, 3 months, 6 months and 1-year post randomisation)
Time Frame
Up to 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults aged ≥16 years of age Able to give written consent, undergoing either: i. Lobectomy or bilobectomy for treatment of known or suspected primary lung cancer beyond lobar orifice* in TNM8 stage cT1-3 (by size criteria, equivalent to TNM7 stage cT1a-2b) or cT3 (by virtue of 2 nodules in the same lobe), N0-1 and M0 or ii. Undergoing frozen section biopsy with the intention to proceed with lobectomy or bilobectomy if primary lung cancer with a peripheral tumour beyond a lobar orifice* in TNM8 stage cT1-3 (by size criteria, equivalent to TNM7 stage cT1a-2b) or cT3 (by virtue of 2 nodules in the same lobe), N0-1 and M0 is confirmed Disease suitable for both minimal access (VATS) and open surgery Exclusion Criteria: Adults lacking capacity to consent Previous malignancy that influences life expectancy Patients in whom a pneumonectomy, segmentectomy or non-anatomic resection (e.g. wedge resection) is planned Patients with a serious concomitant disorder that would compromise patient safety during surgery. Planned robotic surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chris Rogers
Organizational Affiliation
University of Bristol
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Eric Lim
Organizational Affiliation
Royal Brompton & Harefield NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Heartlands Hospital
City
Birmingham
Country
United Kingdom
Facility Name
Bristol Royal Infirmary
City
Bristol
Country
United Kingdom
Facility Name
Royal Infirmary of Edinburgh
City
Edinburgh
Country
United Kingdom
Facility Name
Hull and East Yorkshire Hospitals NHS Trust
City
Hull
Country
United Kingdom
Facility Name
Liverpool Heart and Chest Hospital NHS Foundation Trust
City
Liverpool
Country
United Kingdom
Facility Name
Harefield Hospital
City
London
Country
United Kingdom
Facility Name
Royal Brompton Hospital
City
London
Country
United Kingdom
Facility Name
The James Cook University Hospital
City
Middlesbrough
Country
United Kingdom
Facility Name
Oxford University Hospitals NHS Foundation Trust
City
Oxford
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31615795
Citation
Lim E, Batchelor T, Shackcloth M, Dunning J, McGonigle N, Brush T, Dabner L, Harris R, Mckeon HE, Paramasivan S, Elliott D, Stokes EA, Wordsworth S, Blazeby J, Rogers CA; VIOLET Trialists. Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study). BMJ Open. 2019 Oct 14;9(10):e029507. doi: 10.1136/bmjopen-2019-029507.
Results Reference
background
Links:
URL
https://bmjopen.bmj.com/content/9/10/e029507.citation-tools
Description
Protocol paper publication

Learn more about this trial

VIdeo Assisted Thoracoscopic Lobectomy Versus Conventional Open LobEcTomy for Lung Cancer

We'll reach out to this number within 24 hrs